

Company Announcement no. 14/2013

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, May 30, 2013

**Veloxis Pharmaceuticals A/S – annulment of warrants and registration of new Articles of Association pursuant thereto**

Today, the Board of Directors of Veloxis Pharmaceuticals A/S (the "Company") has decided to annul 18,728,293 warrants, which the Company has repurchased from a number of employees.

The amendment of the Articles of Association pursuant to the annulment of warrants has today been registered with the Danish Business Authority. The new Articles of Association of Veloxis Pharmaceuticals A/S are attached.

**For more information, please contact:**

Veloxis Pharmaceuticals A/S

Bill Polvino  
President & CEO  
Mobile: +1 917 647 9107  
Email: wjp@veloxis.com

Johnny Stilou  
EVP, Chief Financial Officer  
Mobile: +45 21 227 227  
Email: jst@veloxis.com

**About Veloxis Pharmaceuticals**

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose<sup>®</sup>, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide<sup>®</sup>, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit [www.veloxis.com](http://www.veloxis.com).